The average time from surgery to radioactive iodine therapy was 3 months in Group A and 10.5 months in Group B. Patients in Group B tended to be older and have lower risk cancer than patients in Group A. Despite these differences in patient group characteristics, results demonstrated no differences in thyroid cancer recurrences between the groups. Similarly, the proportion of “diseasefree” patients in each group was not significantly different. This shorter interval (<6 months) between surgery and radioiodine treatment was not associated with improved thyroid cancer outcomes compared with a longer interval (>6 months).
WHAT ARE THE IMPLICATIONS OF THIS STUDY?
This study suggests that the timing of radioactive iodine therapy relative to thyroidectomy did not alter disease outcomes in thyroid cancer. This finding allows for more flexibility in timing when scheduling radioactive iodine therapy following thyroidectomy and, thus, patients can have more input on this timing relative to their life schedule.
— Whitney W. Woodmansee MD
ATA THYROID BROCHURE LINKS
Thyroid Cancer (Papillary and Follicular): http://www.thyroid.org/thyroid-cancer/
Thyroid Cancer (Medullary): http://www.thyroid.org/medullary-thyroid-cancer/
Radioactive Iodine: http://www.thyroid.org/ radioactive-iodine/